Haemonetics Corporation HAE
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.44% | -1.97% | -4.02% | -2.45% | 0.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.44% | -1.97% | -4.02% | -2.45% | 0.91% |
| Cost of Revenue | -2.05% | -7.61% | -13.78% | -11.18% | -6.63% |
| Gross Profit | 2.25% | 2.34% | 3.83% | 4.67% | 7.17% |
| SG&A Expenses | 2.63% | 3.10% | 0.97% | 0.83% | 1.27% |
| Depreciation & Amortization | -9.27% | -8.83% | -5.46% | 9.58% | 27.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.66% | -3.39% | -7.00% | -4.72% | -1.44% |
| Operating Income | 5.64% | 4.85% | 10.93% | 9.06% | 13.71% |
| Income Before Tax | -38.04% | -39.63% | 37.89% | 36.67% | 43.23% |
| Income Tax Expenses | -27.64% | -30.79% | 49.15% | 39.57% | 47.01% |
| Earnings from Continuing Operations | -41.05% | -41.97% | 34.88% | 35.84% | 42.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.05% | -41.97% | 34.88% | 35.84% | 42.17% |
| EBIT | 5.64% | 4.85% | 10.93% | 9.06% | 13.71% |
| EBITDA | 2.54% | 2.36% | 7.30% | 8.28% | 13.98% |
| EPS Basic | -37.48% | -38.95% | 42.51% | 41.49% | 45.80% |
| Normalized Basic EPS | 8.55% | 0.67% | 14.36% | 5.87% | 5.93% |
| EPS Diluted | -37.68% | -39.03% | 43.25% | 42.27% | 47.02% |
| Normalized Diluted EPS | 8.83% | 1.20% | 14.99% | 6.56% | 6.62% |
| Average Basic Shares Outstanding | -6.31% | -6.26% | -5.53% | -4.04% | -2.33% |
| Average Diluted Shares Outstanding | -6.57% | -6.75% | -6.04% | -4.63% | -2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |